

Resource Summary Report

Generated by [NIF](#) on Aug 31, 2026

Certara

RRID:SCR_021370

Type: Tool

Proper Citation

Certara (RRID:SCR_021370)

Resource Information

URL: <https://www.certara.com/>

Proper Citation: Certara (RRID:SCR_021370)

Description: Provides drug development software and services. Company offers drug development and clinical pharmacology strategy, regulatory strategy, writing and submission, as well as HEOR and market access solutions. Certara serves biopharmaceutical and medical technology customers worldwide.

Synonyms: , Certara USA, Inc., Certara

Resource Type: commercial organization

Keywords: Company, drug development software, drug development services, drug development strategy, clinical pharmacology strategy, regulatory strategy

Resource Name: Certara

Resource ID: SCR_021370

Record Creation Time: 20220129T080355+0000

Record Last Update: 20260829T182708+0000

Ratings and Alerts

No rating or validation information has been found for Certara.

No alerts have been found for Certara.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wang Y, et al. (2026) Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A. NPJ systems biology and applications, 12(1).

Rosen EY, et al. (2026) Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1411.

Bekker A, et al. (2026) Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1). Antimicrobial agents and chemotherapy, 70(2), e0112625.

Basharat Z, et al. (2025) Proteome mining of Yersinia Enterocolitica for drug targets and computational inhibitor identification with ADMET, anti-inflammation potential and formulation characteristics. BioData mining, 18(1), 68.

Zhou XH, et al. (2025) A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055. iScience, 28(6), 112602.

Ishii K, et al. (2024) Crystal structure of Alzheimer's disease phospholipase D3 provides a molecular basis for understanding its normal and pathological functions. The FEBS journal, 291(24), 5398.

Wang J, et al. (2024) Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors. Cell reports. Medicine, 5(9), 101707.

Uoorakkottil I, et al. (2024) Molecular Docking and Antihypertensive Activity of Eupalitin 3-O-???-D-galactopyranoside Isolated from Boerhavia diffusa Linn. Pharmaceutics, 16(12).

Wu K, et al. (2024) Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches. International journal of molecular sciences, 25(23).

Subbiah V, et al. (2023) Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(16), 2988.

Kagami L, et al. (2023) The ACPYPE web server for small-molecule MD topology generation. Bioinformatics (Oxford, England), 39(6).

Fairman K, et al. (2023) An Overview of Physiologically-Based Pharmacokinetic Models for Forensic Science. Toxics, 11(2).

Ligon JA, et al. (2023) A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(2), 341.

Lammi C, et al. (2022) Mechanistic Insights into Angiotensin I-Converting Enzyme Inhibitory Tripeptides to Decipher the Chemical Basis of Their Activity. *Journal of agricultural and food chemistry*, 70(37), 11572.

Teixeira-da-Silva P, et al. (2022) Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients. *Pharmaceutics*, 14(4).

Crudo F, et al. (2022) Persistence of the antagonistic effects of a natural mixture of *Alternaria* mycotoxins on the estrogen-like activity of human feces after anaerobic incubation. *Toxicology letters*, 358, 88.

Chen FW, et al. (2022) Activation of mitochondrial TRAP1 stimulates mitochondria-lysosome crosstalk and correction of lysosomal dysfunction. *iScience*, 25(9), 104941.

Fouqueray P, et al. (2021) Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. *Cell reports. Medicine*, 2(12), 100474.

Crudo F, et al. (2021) An in vitro study on the transport and phase II metabolism of the mycotoxin alternariol in combination with the structurally related gut microbial metabolite urolithin C. *Toxicology letters*, 340, 15.

Luo T, et al. (2021) Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks. *Frontiers in pharmacology*, 12, 711126.